NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free VCEL Stock Alerts $48.10 -0.55 (-1.13%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$47.64▼$49.0250-Day Range$43.74▼$52.9052-Week Range$30.18▼$53.05Volume315,714 shsAverage Volume363,921 shsMarket Capitalization$2.34 billionP/E RatioN/ADividend YieldN/APrice Target$46.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vericel alerts: Email Address Vericel MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2.7% Downside$46.80 Price TargetShort InterestBearish9.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 34 Articles This WeekInsider TradingSelling Shares$2.45 M Sold Last QuarterProj. Earnings Growth390.00%From $0.10 to $0.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.72 out of 5 starsMedical Sector861st out of 925 stocksBiological Products, Except Diagnostic Industry147th out of 154 stocks 1.5 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has only been the subject of 2 research reports in the past 90 days.Read more about Vericel's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.22% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Vericel has recently decreased by 1.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 3.2 News and Social Media Coverage News SentimentVericel has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Vericel this week, compared to 4 articles on an average week.Search Interest2 people have searched for VCEL on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,450,996.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow by 390.00% in the coming year, from $0.10 to $0.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -4,805.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -4,805.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 10.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Vericel Stock (NASDAQ:VCEL)Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More VCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCEL Stock News HeadlinesApril 21, 2024 | insidertrades.comDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) StockApril 20, 2024 | insidertrades.comVericel Co. (NASDAQ:VCEL) CEO Sells $780,325.00 in StockMay 12, 2024 | The Freeport Society (Ad)Biden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?May 12, 2024 | americanbankingnews.comHC Wainwright Boosts Vericel (NASDAQ:VCEL) Price Target to $55.00May 12, 2024 | americanbankingnews.comVericel (NASDAQ:VCEL) Stock Rating Lowered by StockNews.comMay 11, 2024 | markets.businessinsider.comVericel’s Strong Q1 Performance and Growth Potential Affirm Buy RatingMay 11, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Vericel Co.'s Q1 2025 Earnings (NASDAQ:VCEL)May 11, 2024 | americanbankingnews.comVericel Co. to Post Q1 2025 Earnings of $0.04 Per Share, HC Wainwright Forecasts (NASDAQ:VCEL)May 12, 2024 | The Freeport Society (Ad)Biden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?May 10, 2024 | bloomberg.comVericel Finds Gem in Cartilage Repair: Vanguards of Health CareMay 9, 2024 | markets.businessinsider.comCritical Insights From Vericel Analyst Ratings: What You Need To KnowMay 9, 2024 | finance.yahoo.comVericel First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | finance.yahoo.comVericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...May 8, 2024 | msn.comVCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comVericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core MarketsMay 8, 2024 | seekingalpha.comVericel Corporation 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | finanznachrichten.deVericel Corporation: Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial GuidanceMay 8, 2024 | msn.comVericel GAAP EPS of -$0.08 beats by $0.03, revenue of $51.3M beats by $2.23MMay 8, 2024 | globenewswire.comVericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial GuidanceMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Vericel's earningsMay 7, 2024 | msn.comVericel Q1 2024 Earnings PreviewMay 3, 2024 | americanbankingnews.comVericel Co. (NASDAQ:VCEL) Receives Average Rating of "Buy" from AnalystsMay 2, 2024 | americanbankingnews.comGenocea Biosciences (NASDAQ:GNCAQ) & Vericel (NASDAQ:VCEL) Head to Head ContrastApril 26, 2024 | finance.yahoo.comHere's Why Shareholders May Want To Be Cautious With Increasing Vericel Corporation's (NASDAQ:VCEL) CEO Pay PacketApril 24, 2024 | globenewswire.comVericel to Report First-Quarter 2024 Financial Results on May 8, 2024April 21, 2024 | nz.finance.yahoo.comVericel Corporation (VCEL) stock historical prices & data – Yahoo FinanceApril 17, 2024 | money.usnews.comVericel CorpSee More Headlines Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/12/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees314Year Founded1989Price Target and Rating Average Stock Price Target$46.80 High Stock Price Target$55.00 Low Stock Price Target$39.00 Potential Upside/Downside-2.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio481.00 P/E GrowthN/ANet Income$-3,180,000.00 Net Margins0.22% Pretax Margin0.61% Return on Equity0.21% Return on Assets0.13% Debt Debt-to-Equity RatioN/A Current Ratio5.20 Quick Ratio4.21 Sales & Book Value Annual Sales$197.52 million Price / Sales11.84 Cash Flow$0.02 per share Price / Cash Flow2,729.54 Book Value$4.81 per share Price / Book10.00Miscellaneous Outstanding Shares48,600,000Free Float46,075,000Market Cap$2.34 billion OptionableOptionable Beta1.74 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Dominick C. Colangelo Esq. (Age 60)CEO, President & Director Comp: $1.54MMr. Joseph Anthony Mara Jr. (Age 48)CFO & Treasurer Comp: $750.61kMr. Michael Halpin (Age 62)Chief Operating Officer Comp: $796.91kMr. Sean C. Flynn (Age 50)Chief Legal Officer Comp: $657.01kDr. Jonathan M. Hopper FRCSEd. (Age 62)M.B. Ch.B., Chief Medical Officer Comp: $672.16kMr. Jonathan D. SiegalPrincipal Accounting Officer, VP & Corporate ControllerMr. Eric BurnsVice President of Finance & Investor RelationsMr. Patrick J. FowlerSenior Vice President of Corporate Development & StrategyMr. Patrick HelfrichVice President of Marketing & Commercial StrategyMr. Mike GilliganSenior Vice President of SalesMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLIKymera TherapeuticsNASDAQ:KYMRTwist BioscienceNASDAQ:TWSTCG OncologyNASDAQ:CGONApogee TherapeuticsNASDAQ:APGEView All CompetitorsInsiders & InstitutionsSummit Creek Advisors LLCSold 93,529 shares on 5/11/2024Ownership: 0.718%Hillsdale Investment Management Inc.Bought 9,300 shares on 5/11/2024Ownership: 0.247%Vanguard Group Inc.Bought 39,349 shares on 5/10/2024Ownership: 7.055%Lindenwold Advisors INCBought 4,140 shares on 5/10/2024Ownership: 0.009%Dorsey & Whitney Trust CO LLCSold 1,329 shares on 5/9/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VCEL Stock Analysis - Frequently Asked Questions Should I buy or sell Vericel stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCEL shares. View VCEL analyst ratings or view top-rated stocks. What is Vericel's stock price target for 2024? 6 brokers have issued 12-month price targets for Vericel's stock. Their VCEL share price targets range from $39.00 to $55.00. On average, they expect the company's share price to reach $46.80 in the next year. This suggests that the stock has a possible downside of 2.7%. View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts. How have VCEL shares performed in 2024? Vericel's stock was trading at $35.61 at the beginning of 2024. Since then, VCEL stock has increased by 35.1% and is now trading at $48.10. View the best growth stocks for 2024 here. When is Vericel's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our VCEL earnings forecast. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) issued its earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. The biotechnology company earned $51.28 million during the quarter, compared to the consensus estimate of $49.07 million. Vericel had a trailing twelve-month return on equity of 0.21% and a net margin of 0.22%. Vericel's revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.16) EPS. What ETFs hold Vericel's stock? ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), WisdomTree BioRevolution Fund (WDNA), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Syntax Stratified SmallCap ETF (SSLY). What guidance has Vericel issued on next quarter's earnings? Vericel updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $238.0 million-$242.0 million, compared to the consensus revenue estimate of $239.2 million. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA). Who are Vericel's major shareholders? Vericel's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.06%), Conestoga Capital Advisors LLC (4.82%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.11%), William Blair Investment Management LLC (1.74%), Congress Asset Management Co. MA (1.73%) and Geneva Capital Management LLC (1.40%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VCEL) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
